Pfizer to reach carbon net-zero by 2040
Pfizer plans to reduce greenhouse gas emissions by 95 percent, moving away from fossil fuels to reach net-zero 10 years ahead of global target.
List view / Grid view
News
![Takeda logo on a building in San Diego, California 2020 [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Takeda-1-300x278.jpg)
![Takeda logo on a building in San Diego, California 2020 [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Takeda-1-e1641995614300.jpg)
Phase III trial shows lanadelumab reduces HAE attacks in children
Takeda has announced late-breaking Phase III trial data showing that Takhzyro® (lanadelumab) reduces hereditary angioedema (HAE) attacks by roughly 95 percent in children aged two to
Optimising Bacillus spores for sporicidal efficacy assessments
Study reveals that different Bacillus strains sporulate better in different media and conditions, establishing optimal parameters to produce spores for disinfectant efficacy studies.
Lonza to build €500m fill and finish facility in Stein
The large-scale commercial drug product fill and finish facility will be built at Lonza’s existing site in Stein, Switzerland, with completion expected in 2026.
Controlling contamination by material transfer
Here, EPR summarises Tim Sandle's review of different methods for transferring items into aseptic areas, including decontamination chambers and pass-through hatches.
How should cleaning validation sampling locations be chosen?
Here EPR summarises the salient points of a case study, presenting a strategy for identifying worst-case sampling locations on equipment for cleaning validation.
Continuous treatment with Kesimpta sees RMS patients achieving NEDA-3
Study highlights benefit of initiating high-efficacy therapies early for relapsing multiple sclerosis (RMS) patients, as opposed to changing from lower efficacy therapies later.
Biopharmaceutical bioseparation systems market to value $20bn
With demand for biopharmaceuticals rising and advances being made in bioseparation systems, the global market it expected to witness significant growth.
Healthier Together and philanthropic ventures in tropical disease
Europe launches the EU Non-communicable diseases (NCDs) initiative, while GSK and Novartis promise millions to support drug R&D for neglected tropical diseases and malaria.
![Alexion Pharmaceuticals company logo displayed on a smart phone screen [Credit: IgorGolovniov/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Alexion-1-e1656323649599-300x278.jpg)
![Alexion Pharmaceuticals company logo displayed on a smart phone screen [Credit: IgorGolovniov/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Alexion-1-e1656323657672.jpg)
Alexion to expand biologics manufacturing with €65m investment
The investment in new drug substance production equipment and warehousing facilities to enhance Alexion’s biologics manufacturing in Ireland.
BioNTech launches African vaccine production in Rwanda
Marking the initiation of its African vaccine manufacturing network, BioNTech begins construction of its hub site in Rwanda.
Greece slaps Novartis with €214 million bribery suit
The Greek state is seeking millions in compensation for non-economic damages that may have resulted from Novartis allegedly bribing both government officials and doctors.
Topline results show eplontersen slows disease progression in polyneuropathy patients
Data in the NEURO-TTRansform study demonstrates that eplontersen had a positive impact on disease progression, including improvement in neuropathy impairment and quality of life in a substantial number of patients.
Moderna announces UK mRNA Innovation and Technology Centre
Moderna to establish a UK mRNA Innovation and Technology Centre to produce mRNA vaccines for COVID-19, influenza, respiratory syncytial virus (RSV) and more.
AEX-MS to become increasingly important in antibody characterisation
Study shows AEX-MS enables the analysis of IgG4 Fc deamidation variants and, as IgG4 antibodies become more popular, could become increasingly valuable for antibody charge heterogeneity characterisation.
